Bio Green Med Solution (BGMS) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
1 May, 2026Executive summary
The 2026 Annual Meeting will be held virtually on June 18, 2026, allowing global participation and reducing costs and environmental impact.
Stockholders will vote on the re-election of two Class I directors, ratification of the independent auditor, and an advisory say-on-pay vote for executive compensation.
The Board unanimously recommends voting FOR all proposals.
Only holders of Common Stock as of April 20, 2026, are entitled to vote; Preferred Stock holders are not eligible for current proposals.
Voting matters and shareholder proposals
Proposal 1: Re-election of Dr. Satis Waran Nair Krishnan and Inigo Angel Laurduraj as Class I directors for a three-year term.
Proposal 2: Ratification of SFAI Malaysia Plt. as independent auditors for fiscal year 2026.
Proposal 3: Advisory approval of executive compensation (say-on-pay).
Board recommends FOR all proposals; plurality required for director election, majority for other proposals.
Board of directors and corporate governance
The Board consists of five directors divided into three classes, with staggered three-year terms.
Board diversity includes both male and female directors, with representation from Asian backgrounds.
Three standing committees: Audit, Compensation and Organization, and Nominating and Corporate Governance, all composed of independent directors.
Directors are expected to attend all meetings; 100% attendance reported post-change of control in 2025.
Governance policies emphasize independence, diversity, and regular self-evaluation.
Latest events from Bio Green Med Solution
- Shareholders will virtually vote on directors, auditor ratification, and executive pay, all recommended for approval.BGMS
Proxy filing27 Apr 2026 - Net loss narrowed to $3.0 million in 2025 as fire safety revenue reached $0.7 million.BGMS
Q4 202530 Mar 2026 - Lower Q2 loss and R&D spend, but cash runway and compliance risks persist.BGMS
Q2 20241 Feb 2026 - FADRA demonstrates durable responses in biomarker-driven cancer trials; PLOGO reformulation underway.BGMS
H.C. Wainwright 26th Annual Global Investment Conference 202421 Jan 2026 - Stockholders will vote on key proposals that could shift control and restructure the company's capital.BGMS
Proxy Filing2 Dec 2025 - Shareholders to vote on equity issuances, reverse split, and governance changes to secure funding.BGMS
Proxy Filing2 Dec 2025 - Shareholders to vote on equity issuances, reverse split, and governance changes to ensure compliance.BGMS
Proxy Filing2 Dec 2025 - Virtual annual meeting to vote on directors, equity plan amendment, and executive pay.BGMS
Proxy Filing2 Dec 2025 - Virtual meeting to vote on director elections, equity plan amendment, and executive pay.BGMS
Proxy Filing2 Dec 2025